과제정보
This study was supported by the National Research Foundation, funded by the Ministry of Science and ICT (NRF-2019R1C1C1008181) and the Ministry of Education (NRF-2021R1A6A1A10044950).
참고문헌
- Ayala-Aguilera, C.C., Valero, T., Lorente-Macias, A., Baillache, D.J., Croke, S., and Unciti-Broceta, A. (2022). Small molecule kinase inhibitor drugs (1995-2021): medical indication, pharmacology, and synthesis. J. Med. Chem. 65, 1047-1131. https://doi.org/10.1021/acs.jmedchem.1c00963
- Chan, J.M., Zaidi, S., Love, J.R., Zhao, J.L., Setty, M., Wadosky, K.M., Gopalan, A., Choo, Z.N., Persad, S., Choi, J., et al. (2022). Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling. Science 377, 1180-1191. https://doi.org/10.1126/science.abn0478
- Heo, Y.J., Hwa, C., Lee, G.H., Park, J.M., and An, J.Y. (2021). Integrative multi-omics approaches in cancer research: from biological networks to clinical subtypes. Mol. Cells 44, 433-443. https://doi.org/10.14348/molcells.2021.0042
- Katoh, M. (2019). Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat. Rev. Clin. Oncol. 16, 105-122. https://doi.org/10.1038/s41571-018-0115-y
- Liu, H., Zhang, B., and Sun, Z. (2020). Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis. Cancer Commun. (Lond.) 40, 43-59. https://doi.org/10.1002/cac2.12005
- Zheng, J., Zhang, W., Li, L., He, Y., Wei, Y., Dang, Y., Nie, S., and Guo, Z. (2022). Signaling pathway and small-molecule drug discovery of FGFR: a comprehensive review. Front. Chem. 10, 860985. https://doi.org/10.3389/fchem.2022.860985
- Zingg, D., Bhin, J., Yemelyanenko, J., Kas, S.M., Rolfs, F., Lutz, C., Lee, J.K., Klarenbeek, S., Silverman, I.M., Annunziato, S., et al. (2022). Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature 608, 609-617. https://doi.org/10.1038/s41586-022-05066-5